Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations

Inclusion Criteria: * provide written informed consent prior to enrollment * be a non-smoking male, American Society of Anesthesiologist (ASA) physical class 1 or 2 * have a BMI between 18.5 and 25 kg. inclusive, and a weight of at least 60 kg * be willing and able to participate for the duration of the study * be healthy on the basis of pre-study physical examination (PE), medical history review, vital signs, lab test results as specified in the protocol * negative urine drug test results * negative alcohol screening test * negative antibody test results for hepatitis B, hepatitis C, and HIV Exclusion Criteria: * allergic to bupivacaine, or other amide local anesthetics, or the excipients in the LIQ865 formulations or the diluent * has taken any concomitant medications or supplements for the 3 days prior to Day 0 * has been on blood thinner or medication affecting platelet formation for the 7 days prior to Day 0 * in the opinion of the investigator, is either a hyper or hypo-responder to screening sensitivity testing * has a history of moderate or severe renal or hepatic impairment, moderate or severe active hepatic disease, or any other clinically significant medical condition that may preclude safe study participation * has a clinically significant test result for any screening lab parameter * has a history or ECG screening documentation of a clinically meaningful conduction abnormality * has scarring, tattoos, infections, or other skin changes in the area of planned study medication injection * has known neurological disease or dysfunction (central or peripheral) that may interfere with assessments * is unable to adequately communicate with study staff, properly give informed consent, or otherwise comply with study procedures, particularly the ability to return for outpatient follow up visits * has participated in another interventional clinical study (investigational or marketed product) within the 30 days prior to Day 0.